Clinical Trials Directory

Trials / Completed

CompletedNCT04018885

A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris

A Multi-center, Open, Randomized, Parallel Group Study to Assess Safety, Tolerance and Preliminary Efficacy of ALA for the Treatment of Moderate to Severe Acne Vulgaris

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to explore the safety, tolerability, and preliminary efficacy of ALA used with photodynamic therapy for the treatment of moderate to severe acne vulgaris.

Conditions

Interventions

TypeNameDescription
DRUGALA 2.5%Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
DRUGALA 5%Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
DRUGALA 10%Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Timeline

Start date
2019-07-11
Primary completion
2020-01-20
Completion
2020-01-20
First posted
2019-07-15
Last updated
2020-06-02

Locations

4 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04018885. Inclusion in this directory is not an endorsement.